Fresenius Medical Care AG (BIT:1FME)
Italy · Delayed Price · Currency is EUR | Market Cap | 9.96B -33.2% |
| Revenue (ttm) | 19.36B -0.7% |
| Net Income | 944.68M +52.8% |
| EPS | 3.29 +56.3% |
| Shares Out | n/a |
| PE Ratio | 10.54 |
| Forward PE | 28.57 |
| Dividend | 1.49 (4.00%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | 95 |
| Open | 37.28 |
| Previous Close | 37.24 |
| Day's Range | 37.01 - 37.28 |
| 52-Week Range | 34.68 - 52.46 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial StatementsNews
Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch o...
Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalization New research focuses on applying real-...
Fresenius Medical announces EUR 1B share buyback program
Fresenius Medical (FMS) Care intends to execute a new share buyback program with a total volume of around EUR 1B. The program shall be executed in tranches over a period…
Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
Total volume of the share buyback is around EUR 1 billion over 12 months Share buyback expected to begin in the near future BAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (F...
EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care AG resolves share buyback program with a total volume of around EUR 1 billion in tranches
EQS-Ad-hoc: Fresenius Medical Care AG / Key word(s): Capital measures / Share buybacks Fresenius Medical Care AG : Fresenius Medical Care AG resolves share buyback program with a total volume of aroun...
A Look at Fresenius Medical Care AG (FMS) After 3.8% Decline -- GF Value $24.03 vs Price $21.64
A Look at Fresenius Medical Care AG (FMS) After 3.8% Decline -- GF Value $24.03 vs Price $21.64
EQS-PVR: Fresenius Medical Care AG: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG 22.05.2026 /...
EQS-NVR: Fresenius Medical Care AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Total Voting Rights Announcement: Fresenius Medical Care AG / Total Voting Rights Announcement Fresenius Medical Care AG: Release according to Article 41 of the WpHG [the German Securities Trading...
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
Shareholders approve proposed dividend of EUR 1.49 per share FME Reignite strategy launched in 2025 successfully drives the next phase of value creation 5008X CAREsystem introduced in U.S. clinics; fu...
Fresenius Medical Care AG Annual Shareholders Meeting Transcript
Fresenius Medical Care AG Annual Shareholders Meeting Transcript
Fresenius Medical Care AG Transcript: AGM 2026
The AGM highlighted robust financial growth, a successful transformation program, and the launch of a new five-year strategy. Leadership changes, a dividend increase, and a major U.S. product rollout were announced, with continued focus on innovation and operational excellence.
Fresenius Medical reappoints CFO Martin Fischer
The Supervisory Board of Fresenius Medical (FMS) Care has reappointed CFO and Management Board Member Martin Fischer for a period of five years until 2031.
Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
BAD HOMBURG, Germany, May 20, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, today h...
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
Fresenius Medical Care AG (FMS) Shares Fall 3.8% -- What GF Score of 77 Tells Investors
Fresenius Medical Care AG (FMS) Shares Fall 3.8% -- What GF Score of 77 Tells Investors
Fresenius Medical Care AG Slides: Investor presentation
Fresenius Medical Care AG has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Fresenius Medical price target lowered to EUR 40 from EUR 42 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Fresenius Medical (FMS) to EUR 40 from EUR 42 and keeps a Hold rating on the shares.
Fresenius Medical price target lowered to EUR 33 from EUR 34 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Fresenius Medical (FMS) to EUR 33 from EUR 34 and keeps an Underweight rating on the shares. Published first…
Relative Strength Alert For Fresenius Medical Care
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
EQS-CMS: Fresenius Medical Care AG : Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] Fresenius Medical Care ...
Fresenius Medical Care AG Earnings Call Transcript: Q1 2026
Solid Q1 performance with 4% organic revenue and 10% operating income growth, driven by margin expansion, FME25+ savings, and accelerated 5008X rollout. Outlook for 2026 remains stable, with inflation and regulatory risks closely monitored.
Fresenius Medical Care AG Slides: Q1 2026
Fresenius Medical Care AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Fresenius Medical Care AG Quarterly report: Q1 2026
Fresenius Medical Care AG has published its Q1 2026 quarterly earnings report on May 5, 2026.
Fresenius Medical reports Q1 EPS ex-items EUR0.91 vs. EUR0.84 last year
Reports Q1 revenue EUR4.612B vs. EUR4.881B last year. “Fresenius Medical (FMS) Care delivered continued operational and financial progress in the Q1, with organic revenue growth, improved profitabilit...
Fresenius Medical sees FY26 revenue EUR19.628B
In 2026, Fresenius Medical (FMS) Care expects revenue growth to be broadly flat compared to prior year. The company expects operating income to remain on a consistent level, with a…